File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Serum beta-2 microglobulin predicts mortality after acute coronary syndrome

TitleSerum beta-2 microglobulin predicts mortality after acute coronary syndrome
Authors
Issue Date2019
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/
Citation
24th Medical Research Conference, Department of Medicine, The University of Hong Kong, Hong Kong, 19 January 2019. In Hong Kong Medical Journal, 2019, v. 25 n. 1, Suppl. 1, p. 38 How to Cite?
AbstractIntroduction: We have previously shown that serum beta-2 microglobulin (B2M) is significantly elevated in patients with acute coronary syndrome (ACS) in Hong Kong and is a predictor of all-cause mortality in the United States National Health and Nutritional Examination Survey. In this cohort study, we investigated the relationship between baseline B2M level and mortality in long-term follow-up. Methods: In total, 88 patients with ACS and 79 controls matched for age and sex were recruited from Queen Mary Hospital between September 2015 and May 2016. Serum B2M was measured using a latex-enhanced B2M immunoassay (Siemens Diagnostics, Erlangen, Germany). Patient data up to 15 November 2018 were extracted from the Clinical Data Analysis and Reporting System of the Hong Kong Hospital Authority. Serum B2M levels were compared using analysis of variance with SPSS (Windows version 25.0; IBM Corp, Armonk [NY], United States). Results: Seven patients died (6 in the ACS group) during the follow-up period. The geometric mean of serum B2M level was 3.13 μg/mL (95% confidence interval [CI]=2.14-4.58 μg/mL) in those who died and 1.97 μg/mL (95% CI=1.84-2.11 μg/mL) in those who survived (P=0.001). In the ACS group, the geometric mean serum B2M level was 3.50 μg/mL (95% CI= 2.73-4.49 μg/mL) in those who died and 1.99 μg/mL (95% CI=1.78-2.23 μg/mL) in those who survived (P=0.002). Conclusion: Elevated serum B2M level is associated with higher mortality in patients with ACS. This test is readily available and may help to identify high-risk patients with ACS.
Persistent Identifierhttp://hdl.handle.net/10722/269505
ISSN
2019 Impact Factor: 1.679
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorSo, ASC-
dc.contributor.authorTsoi, MF-
dc.contributor.authorCheung, CL-
dc.contributor.authorLee, SW-
dc.contributor.authorTsui, SH-
dc.contributor.authorChan, EYT-
dc.contributor.authorTam, FCC-
dc.contributor.authorCheung, BMY-
dc.date.accessioned2019-04-24T08:09:03Z-
dc.date.available2019-04-24T08:09:03Z-
dc.date.issued2019-
dc.identifier.citation24th Medical Research Conference, Department of Medicine, The University of Hong Kong, Hong Kong, 19 January 2019. In Hong Kong Medical Journal, 2019, v. 25 n. 1, Suppl. 1, p. 38-
dc.identifier.issn1024-2708-
dc.identifier.urihttp://hdl.handle.net/10722/269505-
dc.description.abstractIntroduction: We have previously shown that serum beta-2 microglobulin (B2M) is significantly elevated in patients with acute coronary syndrome (ACS) in Hong Kong and is a predictor of all-cause mortality in the United States National Health and Nutritional Examination Survey. In this cohort study, we investigated the relationship between baseline B2M level and mortality in long-term follow-up. Methods: In total, 88 patients with ACS and 79 controls matched for age and sex were recruited from Queen Mary Hospital between September 2015 and May 2016. Serum B2M was measured using a latex-enhanced B2M immunoassay (Siemens Diagnostics, Erlangen, Germany). Patient data up to 15 November 2018 were extracted from the Clinical Data Analysis and Reporting System of the Hong Kong Hospital Authority. Serum B2M levels were compared using analysis of variance with SPSS (Windows version 25.0; IBM Corp, Armonk [NY], United States). Results: Seven patients died (6 in the ACS group) during the follow-up period. The geometric mean of serum B2M level was 3.13 μg/mL (95% confidence interval [CI]=2.14-4.58 μg/mL) in those who died and 1.97 μg/mL (95% CI=1.84-2.11 μg/mL) in those who survived (P=0.001). In the ACS group, the geometric mean serum B2M level was 3.50 μg/mL (95% CI= 2.73-4.49 μg/mL) in those who died and 1.99 μg/mL (95% CI=1.78-2.23 μg/mL) in those who survived (P=0.002). Conclusion: Elevated serum B2M level is associated with higher mortality in patients with ACS. This test is readily available and may help to identify high-risk patients with ACS.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/-
dc.relation.ispartofHong Kong Medical Journal-
dc.relation.ispartof24th Medical Research Confernece, Department of Medicine, The University of Hong Kong-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.-
dc.titleSerum beta-2 microglobulin predicts mortality after acute coronary syndrome-
dc.typeConference_Paper-
dc.identifier.emailCheung, CL: lung1212@hku.hk-
dc.identifier.emailTam, FCC: fcctam@hku.hk-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.authorityCheung, CL=rp01749-
dc.identifier.authorityCheung, BMY=rp01321-
dc.identifier.hkuros297283-
dc.identifier.volume25-
dc.identifier.issue1, Suppl. 1-
dc.identifier.spage38-
dc.identifier.epage38-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats